About Qualigen Therapeutics, Inc
Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California. Address: 2042 Corte Del Nogal, Carlsbad, CA, United States, 92011
Qualigen Therapeutics, Inc News and around…
Latest news about Qualigen Therapeutics, Inc (QLGN) common stock and company :
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hote
Gainers Kiromic BioPharma (NASDAQ:KRBP) shares moved upwards by 17.3% to $0.4 during Wednesday's pre-market session. ...
CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its financial results for the first quarter ended March 31, 2022, and provides an update on its diagnostics business, therapeutics pipeline, and other corporate developments. Corporate Highlights During Q
Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that NanoSynex Ltd, a company with whom Qualigen recently entered into definitive agreements to acquire
Gainers Biohaven Pharma Hldgs (NYSE:BHVN) stock moved upwards by 72.6% to $143.49 during Tuesday's pre-market ...
Qualigen Therapeutics Inc(NASDAQ: QLGN) hasagreed to acquire a majority stakeinNanoSynex Ltd, an ...
Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has entered into definitive agreements to acquire a majority stake in
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and ...
CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company’s newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company’s diagnostics division. “Shishir’s consistent leadership
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Licenses G4-Selective Transcription Inhibitors to Develop as Cancer Therapeutics In January 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug program from University College London. The lead compound,
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket. The post Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
Gainers Zosano Pharma (NASDAQ:ZSAN) stock moved upwards by 2670.4% to $3.33 during Tuesday's regular session. Trading volume for this ...
Qualigen Therapeutics Inc(NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer ...
AACR POSTER Structural and Chemical Biology AACR POSTER - CHART 1 New Chemotherapy Agents AACR POSTER - CHART 2 Tumor Volumes for CTG-1128 AACR POSTER - CHART 3 Tumor Volumes for CTG-0952 AACR POSTER - CHART 4 Tumor Volumes for CTG-2184 Data Highlights In Vivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing tr
Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the official resumption as of April 1, 2022 of worldwide distribution and commercial control of FastPack® from previous
CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today announces its financial results for the fiscal year ended December 31, 2021. “Our financial results for 2021 are highlighted by a 31% increase in revenue over 2020 in our diagnostics business, which includes incr
CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has appointed the renowned contract research organization (CRO) Translational Drug Development (TD2) to lead the preclinical development of lead drug candidate QN-302. Qualigen is initially investiga
Abstracts Review Positive In vivo Data and the Potential Mechanism of Action for QN-302 in Pancreatic and Prostate Cancers CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today provides data from published abstracts from the American Association of Cancer Research (AACR) demons
CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today announces the mutual extension of a research agreement with University of Louisville Research Foundation (ULRF). The revised agreement expands the Company’s collaboration with the research institution to develop
Gainers Eargo (NASDAQ:EAR) shares rose 10.9% to $5.29 during Wednesday's after-market session. Today's trading volume for this ...
Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million ...
Gainers Indonesia Energy Corporation Limited (NYSE: INDO) shares climbed 66.7% to $12.55 following a 16% surge on ...
Gainers Imperial Petroleum Inc.(NASDAQ: IMPP) rose 45.1% to $1.64 in pre-market trading after gaining around 41% on ...
Gainers Revelation Biosciences (NASDAQ:REVB) stock moved upwards by 30.0% to $2.0 during Tuesday's after-market session. Today's ...
CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation and diagnostics, today issues the following Letter to Shareholders: To Our Valued Shareholders: As we close out the second month of 2022, I am excited for what lies ahead for our company. The last 45 days have helped to realize the well-constructed strategy of
Posters to be Presented During the In-Person Conference Being Held April 8-13, 2022 in New Orleans CARLSBAD, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces that three abstracts on aspects of the Company’s recently in-licensed compound from University College -London, QN-302, have been accepted as posters to be
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 ...
Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announced that it has engaged Professor Stephen Neidle as a scientific advisor. Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the
Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, including lead and back-up compounds, preclinical data
Qualigen Therapeutics, Inc (QLGN) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare